SUBSCRIBE
SUBSCRIBE

BioSpace Insights

The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.

Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
In this episode of Denatured, you’ll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therapeutics. We’ll be speaking about patient-pharma collaborations accelerating trials and hope, advances in ALS biology understanding and biomarker-driven endpoints.
February 26, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
IN PARTNERSHIP WITH API
Webinar: Lean Derisking: Taking Your Proof of Concept to the Clinic
Taking an early proof of concept into preclinical and clinical development is a costly and complex process. But there are strategic ways to streamline the process and reduce risk and costs. In this webinar, you’ll hear directly from Nobel Laureate Sir Michael Houghton and experts from Applied Pharma, who bring decades of real-world success and deep scientific expertise.
February 24, 2026
 · 
1 min read
 · 
BioSpace Insights
Insights
Historic ALS Investment Signals New Treatment Momentum
The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics’ first patient dosing in its TDP-43-targeting PIONEER-ALS trial and EverythingALS’ pharma consortia driving biomarker innovations and trial alignment.
February 23, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
February 19, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
In the incredibly hot obesity drug space, with more than 700 clinical trials ongoing, Verdiva Bio and MitoRx leaders discuss how next-generation therapies are targeting lean muscle preservation, extended efficacy and better safety profiles to enable lifelong weight management.
February 19, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Insights
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe and Jennifer Fakish at Danaher Corporation. They discuss how antibody drug conjugates (ADCs) are transforming cancer care. With AI-powered pathology, doctors can now measure HER2 more precisely to match patients with the best treatments.
February 12, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
CAREER ADVICE
Webinar: 2026 Hiring Trends and Job Market Signals
This webinar provides a clear-eyed assessment of current hiring conditions across biopharma, exploring which roles and skills are in demand, where opportunities are emerging, and how hiring practices are evolving.
February 10, 2026
 · 
1 min read
 · 
BioSpace Insights
Her-2 - Test with blood sample. Top view isolated on office desk. Healthcare or Medical concept
Insights
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low and ultra-low expressors, match patients to the right therapies and make more precise treatment decisions.
February 10, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
February 5, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
A close-up of a zebra standing in the Okavango Delta, showcasing its distinctive black and white stripes. The background is a blur of natural vegetation.
Insights
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
Investor enthusiasm and evolving FDA pathways are accelerating rare disease drug development, with ultrarare conditions like MPS II moving into the spotlight.
February 4, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Array of piggy banks in saturated colours on high colour contrast background. Illustration of the concept of bank savings, financial investment and multiple sources of income
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
January 29, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Insights
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how “alpha stacking” shapes their investment edge in an age of chronic uncertainty. They cover topics discussed in RTW’s new book, “Innovation is the Best Medicine.”
January 29, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Employer Resources
Report: 2026 Employment Outlook
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
January 28, 2026
 · 
1 min read
 · 
BioSpace Insights
Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking to a range of pharma and biotech executives and investors last week.
January 22, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
MRI or magnetic resonance imaging of the head and brain. Close up
Insights
The New Gold Rush in Brain Science
Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, even amid costly setbacks. BioSpace spoke to investors at JPM26 to get their take on recent bets in new therapies and neurotech.
January 22, 2026
 · 
5 min read
 · 
Jennifer Smith-Parker
Load More